Fractyl Health (GUTS) Free Cash Flow (2023 - 2026)
Fractyl Health (GUTS) reported Free Cash Flow of -$22.5 million for Q1 2026, up 11.95% year-on-year from -$20.1 million in Q1 2025, and down 5.33% quarter-over-quarter from -$21.3 million in Q4 2025.
Fractyl Health (GUTS) has 4 years of Free Cash Flow data on file, last reported at -$22.5 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 11.95% year-over-year to -$22.5 million; the trailing twelve-month figure through Mar 2026 stood at -$87.8 million (down 8.33% YoY), and the FY2025 full-year result was -$90.9 million, down 35.07% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$22.5 million, down from -$21.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$9.6 million in Q1 2023 and bottomed at -$25.5 million in Q1 2025.
- A 4-year average of -$17.2 million and a median of -$18.3 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow sank 117.6% in 2025 and rose 11.95% in 2026, its largest moves.
- Tracing GUTS's Free Cash Flow over 4 years: stood at -$10.7 million in 2023, then tumbled by 61.84% to -$17.3 million in 2024, then retreated by 23.58% to -$21.3 million in 2025, then decreased by 5.33% to -$22.5 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$22.5 million, -$21.3 million, and -$22.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 848.30 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | -22.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.48 Mn |
| Mar 31, 2026 | -22.48 Mn |
| Dec 31, 2025 | -21.34 Mn |
| Dec 31, 2025 | -21.34 Mn |
| Sep 30, 2025 | -22.72 Mn |
| Sep 30, 2025 | -22.72 Mn |
| Jun 30, 2025 | -21.30 Mn |
| Jun 30, 2025 | -21.30 Mn |
| Mar 31, 2025 | -25.53 Mn |
| Mar 31, 2025 | -25.53 Mn |
| Dec 31, 2024 | -17.27 Mn |
| Dec 31, 2024 | -17.27 Mn |
| Sep 30, 2024 | -18.25 Mn |
| Sep 30, 2024 | -18.25 Mn |
| Jun 30, 2024 | -20.04 Mn |
| Jun 30, 2024 | -20.04 Mn |
| Mar 31, 2024 | -11.73 Mn |
| Mar 31, 2024 | -11.73 Mn |
| Dec 31, 2023 | -10.67 Mn |
| Dec 31, 2023 | -10.67 Mn |
| Sep 30, 2023 | -10.96 Mn |
| Sep 30, 2023 | -10.96 Mn |
| Jun 30, 2023 | -11.71 Mn |
| Jun 30, 2023 | -11.71 Mn |
| Mar 31, 2023 | -9.57 Mn |
| Mar 31, 2023 | -9.57 Mn |